Straits Times Index
3,116.31 -49.19 (-1.55%) S&P 500
3,647.29 -7.75 (-0.21%) Dow
29,134.99 -125.82 (-0.43%) Nasdaq
10,829.50 +26.58 (+0.25%) BTC-USD
18,990.29 -1,246.39 (-6.16%) CMC Crypto 200
433.80 -25.33 (-5.52%)
Aditxt, Inc. (ADTX)
Pre-market:
| Previous close | 3.0500 |
| Open | 2.9200 |
| Bid | 3.1800 x 1100 |
| Ask | 3.3400 x 2200 |
| Day's range | 2.7100 - 3.3500 |
| 52-week range | 2.5800 - 136.0000 |
| Volume | |
| Avg. volume | 1,273,871 |
| Market cap | 3.731M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7200 |
| Earnings date | 13 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.00 |
- Business Wire
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
RICHMOND, Va., September 27, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today provides shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering.
- Business Wire
Aditxt Announces Closing of $20.0 Million Public Offering
RICHMOND, Va., September 20, 2022--Aditxt, Inc., (Nasdaq: ADTX) (the "Company" or "Aditxt"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the closing of its previously announced public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the publi
- Business Wire
Aditxt Announces Pricing of $20.0 Million Public Offering
RICHMOND, Va., September 16, 2022--Aditxt, Inc., (Nasdaq: ADTX) (the "Company" or "Aditxt"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the pricing of a public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share (o
